Baird Reiterates Neutral Rating on Amgen (AMGN)

Amgen (AMGN) World Lung KRAS Update Supports Rapid Filing Strategy - Oppenheimer

Oppenheimer analyst Jason Helfstein reiterated an Outperform rating and $240.00 price target on Amgen (NASDAQ: AMGN) after the World Lung (IASLC 2019) data featured an update on AMG 510 (KRAS inhibitor) with a focus on the top dose patients (960mg) in previously treated KRAS G12C+... More

Amgen (AMGN) Phase 1 Data Confirms Expected Response Rate - BMO Capital

BMO Capital analyst Do Kim reiterated an Outperform rating on Amgen (NASDAQ: AMGN) after AMG 510 Phase 1 data released at the 2019 WCLC supports an ORR around 50% in NSCLC, in line with the 50% PR at ASCO.

The analyst stated "While the response rate remained... More

Amgen (AMGN) Thoughts After Ph1 Data - Mizuho

Mizuho Securities analyst Salim Syed reiterated a Neutral rating and $212.00 price target on Amgen (NASDAQ: AMGN) after the company reported additional Phase 1 results from patients with lung cancer treated with AMG 510, KRAS-targeting drug.

The analyst believes that every 10% POS is worth... More

Amgen (AMGN): Durability Will Be A Key 2020 Question - Cantor Fitzgerald

Cantor Fitzgerald analyst Alethia Young reiterated a Neutral rating and $230.00 price target on Amgen (NASDAQ: AMGN) after the company presented updated AMG-510 data at the World Lung medical meeting and hosted a conference call to discuss the data including an additional 20 NSCLC patients... More

Amgen (AMGN) PT Raised to $243 at Goldman Sachs After AMG 510 Lung Cancer Response Rate Data Appears In-Line

Goldman Sachs analyst Terence Flynn raised the price target on Amgen (NASDAQ: AMGN) to $243.00 (from $229.00) after 8 investigators presented updated Ph1/2 lung cancer data for AMGNs pipeline KRAS inhibitor, AMG510.

The analyst stated "In our view the response rate (48%/96% ORR/DCR)... More

Amgen (AMGN) 510 Update at WCLC Consistent with Filing in 2020 - Morgan Stanley

Morgan Stanley anlayst, Matthew Harrison, published an update on Amgen (NASDAQ: AMGN) after the company presented updated PhI data for AMG 510 in patients with NSCLC. The drug previously achieved a 50% objective response rate (ORR) in 10 patients at ASCO and the updated WCLC data... More

Cantor Fitzgerald Reiterates Neutral Rating on Amgen (AMGN)

Cantor Fitzgerald analyst Alethia Young reiterated a Neutral rating and $230.00 price target on Amgen (NASDAQ: AMGN) after the company presented updated AMG-510 data at the World Lung medical meeting and hosted a conference call to discuss the data. This update included an additional... More

Amgen (AMGN) Announces New Data Evaluating Novel Investigational KRAS(G12C) Inhibitor in Larger Patient Group at WCLC

(Updated - September 9, 2019 6:29 AM EDT)

Amgen (NASDAQ: AMGN) today announced new data from the ongoing Phase 1 study evaluating AMG 510 in patients with previously treated KRAS G12C-mutated solid tumors. AMG 510 is a first-in-class investigational oral therapy that is designed to selectively and irreversibly target the KRASG12C protein. The additional follow-up in a larger group of patients with non-small cell lung cancer (NSCLC) continued to show anti-tumor activity with no dose-limiting toxicities. These data are being presented during an oral presentation at IASLC 2019 World Conference on Lung Cancer (WCLC)... More

Amgen (AMGN) PT Raised to $230 at Cantor Fitzgerald Ahead of World Lung

Cantor Fitzgerald analyst Alethia Young raised the price target on Amgen (NASDAQ: AMGN) to $230.00 (from $221.00) while maintaining a Neutral rating, saying there is a potential for a KRASi move at World Lung this weekend.

Young commented, "Our gut sense is that... More